FDA Approves VUITY Eye Drops As Substitute for Reading Glasses

128 million Americans have presbyopia.

Tech
9,635 Hypes 4 Comments

Allergan’s VUITY eye drops have been approved by the U.S. Food and Drug Administration — used for the treatment of presbyopia.

When looking at the numbers, these eye drops could potentially be used by the 128 million Americans with old-age vision impairment that results in the inability to focus on nearby objects. Set to replace the need for reading glasses or surgery, VUITY was tested in two phase-three clinical studies where 750 participants aged 40 – 55 were administered the drops once daily. The results were: better scores on reading charts and improved vision in low light after 30 days.

“We are pleased to be able to bring this first-of-its-kind treatment to market sooner than expected for the millions of Americans with presbyopia who may benefit from it,” said Jag Dosanjh, senior vice president of medical therapeutics of Allergan. “This significant innovation in age-related eye health reflects our commitment to advance vision care and expands our leading portfolio of treatments for eye care providers and their patients.”

In other news, IBM and Samsung say a new chip design could extend phone battery life to a week.

Read Full Article

What to Read Next

Eye/LOEWE/Nature Drops Puffy Pleated Nylon Slides for SS22
Footwear

Eye/LOEWE/Nature Drops Puffy Pleated Nylon Slides for SS22

Choose from neon pink, neon orange, or black.

MLB Approves Wearable Pitch Calling Devices for Regular Season
Sports

MLB Approves Wearable Pitch Calling Devices for Regular Season

“PitchCom” is aimed at reducing sign-stealing and speeding up the game.

Jillian Mayer Unveils Mesmerizing ‘Glass Room’ for Bisquit & Dubouché at Frieze LA 2022
Art 

Jillian Mayer Unveils Mesmerizing ‘Glass Room’ for Bisquit & Dubouché at Frieze LA 2022

Reimagining the cognac’s hues in decadent, tangible forms.


Garbstore Recruits eye_C for SS22 Editorial
Fashion

Garbstore Recruits eye_C for SS22 Editorial

Shot in Bergen, Norway.

'Your Name.' Director Makoto Shinkai Announces New Film 'Suzume no Tojimari'
Entertainment

'Your Name.' Director Makoto Shinkai Announces New Film 'Suzume no Tojimari'

Set for a Fall 2022 release.

WACKO MARIA and nonnative Unveil Converse All Star 100 Hi Collab
Footwear

WACKO MARIA and nonnative Unveil Converse All Star 100 Hi Collab

Both Tokyo-based brands’ signature embellishments adorn the classic high-top silhouette.

Chadwick Boseman's Brother Claims That the Late Actor Would Have Wanted Black Panther Recasted
Entertainment

Chadwick Boseman's Brother Claims That the Late Actor Would Have Wanted Black Panther Recasted

Understanding that T’Challa “was bigger than one guy.”

Rick Ross Entertains the Idea of a 'VERZUZ' Battle With JAY-Z
Music

Rick Ross Entertains the Idea of a 'VERZUZ' Battle With JAY-Z

“Why not?”

Ubisoft Is Finally Remaking 'Splinter Cell'
Gaming

Ubisoft Is Finally Remaking 'Splinter Cell'

And they’re looking for new talent to join the development team.


Here's a First Look at the Potential Union LA x Nike Cortez
Footwear

Here's a First Look at the Potential Union LA x Nike Cortez

In two colorways.

New Study Finds That Logic's "1-800-273-8255" Song Actually Saved Lives
Music

New Study Finds That Logic's "1-800-273-8255" Song Actually Saved Lives

The US National Suicide Prevention Lifeline received almost 10,000 additional calls.

New Digital Marketplace Otis House Turns Rare Collectables Into NFTs
NFT

New Digital Marketplace Otis House Turns Rare Collectables Into NFTs

The first drop includes a Lebron James Rookie card, 3 vintage video games and a Bob Ross painting.

Kevin Durant Is Officially the Face of Crypto Platform Coinbase
Tech

Kevin Durant Is Officially the Face of Crypto Platform Coinbase

The latest NBA star to join in on the crypto craze.

Oreo Stacks up New Toffee Crunch and Ultimate Chocolate Cookie Flavors
Food & Beverage

Oreo Stacks up New Toffee Crunch and Ultimate Chocolate Cookie Flavors

Hitting shelves by early 2022.

More ▾
 
Subscribe to our Newsletter

Gain access to exclusive interviews with industry creatives, think pieces, trend forecasts, guides and more.

By subscribing, you agree to our Terms of Use and Privacy Policy.

Looks like you’re using an ad-blocker

We charge advertisers instead of our readers. Support us by whitelisting our site.

Whitelist Us

How to Whitelist Us

screenshot
  1. Click the AdBlock icon in the browser extension area in the upper right-hand corner.
  2. Under “Pause on this site” click “Always”.
  3. Refresh the page or click the button below to continue.
screenshot
  1. Click the AdBlock Plus icon in the browser extension area in the upper right-hand corner.
  2. Block ads on – This website” switch off the toggle to turn it from blue to gray.
  3. Refresh the page or click the button below to continue.
screenshot
  1. Click the AdBlocker Ultimate icon in the browser extension area in the upper right-hand corner.
  2. Switch off the toggle to turn it from “Enabled on this site” to “Disabled on this site”.
  3. Refresh the page or click the button below to continue.
screenshot
  1. Click the Ghostery icon in the browser extension area in the upper right-hand corner.
  2. Click on the “Ad-Blocking” button at the bottom. It will turn gray and the text above will go from “ON” to “OFF”.
  3. Refresh the page or click the button below to continue.
screenshot
  1. Click the UBlock Origin icon in the browser extension area in the upper right-hand corner.
  2. Click on the large blue power icon at the top.
  3. When it turns gray, click the refresh icon that has appeared next to it or click the button below to continue.
screenshot
  1. Click the icon of the ad-blocker extension installed on your browser.You’ll usually find this icon in the upper right-hand corner of your screen. You may have more than one ad-blocker installed.
  2. Follow the instructions for disabling the ad blocker on the site you’re viewing.You may have to select a menu option or click a button.
  3. Refresh the page or click the button below to continue.